IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR'S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE METASTATIC UVEAL MELANOMA (DAR-UM-2)
Details
Age
Adult
Locations
CTRC Inpatient
Outpatient CTRC
University of Colorado Hospital
Principal Investigator
Luke Mantle
Study ID
Protocol Number: 24-0171
More information available at ClinicalTrials.gov: NCT05987332
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers